Danaher Corporation $DHR Stake Boosted by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC significantly increased its holdings in Danaher Corporation by 3,574.2% during the first quarter, now owning 49,455 shares valued at over $10 million.
• Danaher's stock has a current average rating of "Moderate Buy" from analysts, with a consensus target price of $246.35 based on 17 buy ratings and 3 hold ratings.
• The company reported an earnings per share (EPS) of $1.80 for the last quarter, exceeding analysts' expectations and indicating a 3.4% year-over-year revenue increase.

Acadian Asset Management LLC grew its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 3,574.2% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 49,455 shares of the conglomerate's stock after acquiring an additional 48,109 shares during the period. Acadian Asset Management LLC's holdings in Danaher were worth $10,136,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Heck Capital Advisors LLC bought a new stake in Danaher in the fourth quarter worth $27,000. GHP Investment Advisors Inc. boosted its holdings in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after purchasing an additional 99 shares in the last quarter. Sierra Ocean LLC boosted its holdings in Danaher by 116.9% in the first quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock worth $29,000 after purchasing an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new stake in Danaher in the first quarter worth $31,000. Finally, Dunhill Financial LLC boosted its holdings in Danaher by 68.4% in the first quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate's stock worth $34,000 after purchasing an additional 67 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on DHR shares. Wall Street Zen upgraded shares of Danaher from a "hold" rating to a "buy" rating in a report on Friday, June 27th. Deutsche Bank Aktiengesellschaft decreased their price objective on shares of Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Evercore ISI decreased their price target on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Wells Fargo & Company decreased their price target on shares of Danaher from $210.00 to $205.00 and set an "equal weight" rating for the company in a report on Wednesday, July 23rd. Finally, UBS Group decreased their price target on shares of Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $246.35.

Danaher Stock Down 2.6%

DHR stock opened at $190.07 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The company has a 50-day moving average of $201.21 and a two-hundred day moving average of $198.90. The stock has a market capitalization of $136.10 billion, a price-to-earnings ratio of 40.44, a price-to-earnings-growth ratio of 2.72 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts' expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The business's quarterly revenue was up 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, equities research analysts anticipate that Danaher Corporation will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is currently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director owned 20,751 shares of the company's stock, valued at approximately $4,379,706.06. This represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.